Trade Summary

6 days ago, Knowles Julius, serving as Dir at Keros Therapeutics, Inc. (KROS), sold 2,625 shares at $10.73 per share, for a total transaction value of $28,166.25. Following this transaction, Knowles Julius now holds 10,958 shares of KROS.

This sale represents a 19.33% decrease in Knowles Julius's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, June 4, 2026 and publicly disclosed via SEC Form 4 filing on Monday, June 8, 2026 at 4:36 PM ET, 4 days after the trade was made.

Keros Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.